Feature | June 04, 2015

First U.S. Lumason Echocardiography Imaging Procedure Performed

Contrast agent indicated to opacify left ventricular chamber in suboptimal echocardiograms

Bracco, Lumason, first U.S. echocardiography procedure, Morristown

June 4, 2015 - Bracco Imaging announced that the first echocardiography imaging procedure with Lumason was performed in May at Morristown Medical Center, part of the Atlantic Health System, in New Jersey. This is the first administration after the development of the agent (sulfur hexafluoride lipid-type A microspheres) in the United States and approval by the U.S. Food and Drug Administration. The announcement was made through Bracco Imaging's affiliate Bracco Diagnostics Inc.

 "We're thrilled to be the first medical center to use Lumason in adults with suboptimal echocardiograms," said Linda Gillam, M.D., MPH, FASE, chair of the Gagnon Cardiovascular Institute at Morristown Medical Center. "Now we have an additional option when performing contrast enhanced ultrasound."

Lumason, internationally known as SonoVue in 40 countries, is an ultrasound contrast agent made up of gas-filled microbubbles (or microspheres) that reflect the sound waves to enhance the image.

Lumason has been approved by the FDA for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.

The agent is supplied as a three-part kit. Each kit contains a Lumason vial containing 25 mg of lipid-type A lyophilized powder and 60.7 mg sulfur hexafluoride headspace, a prefilled syringe containing 5 mL of sodium chloride 0.9 percent injection, USP (Diluent), and a Mini-Spike.

For more information: www.braccoimaging.com

Related Content

Ligand Establishes Program to Develop Captisol-Enabled, Next-Generation Diagnostic Imaging Contrast Agents
News | Contrast Media | January 19, 2018
Ligand Pharmaceuticals Inc. announced initiation of a program to develop contrast agents with reduced renal toxicity....
FDA Holds MIDAC Meeting on Gadolinium-Based Contrast Agents. Image by Marilyn Fornell
News | Contrast Media | September 07, 2017
The U.S. Food and Drug Administration (FDA) announced it would hold a meeting of the Medical Imaging Drugs Advisory...
European Medicines Agency Issues Update on Gadolinium Contrast Agents
News | Contrast Media | August 29, 2017
August 29, 2017 — The European Medicines Agency (EMA) issued a final opinion that recommended restricting the use of
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media | July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
ACR Offers Revised Contrast Media in Imaging Manual
News | Contrast Media | July 17, 2017
The American College of Radiology (ACR) recently revised its authoritative guide for the safe and effective use of...
Bayer Arterion contrast Injector used to administer medical imaging contrast for CT scans.

Bayer Healthcare's Arterion contrast injector system.

Feature | Contrast Media | June 19, 2017 | Dave Fornell
Here are several updates in medical imaging...
PRAC, European Medicines Agency, gadolinium-based contrast agents, safety recommendations, brain MRI
News | Contrast Media | March 13, 2017
The Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency recently released new...
Lantheus Medical Imaging, Definity, FDA approval, label update, echocardiography, cardiac shunt contraindication
Technology | Contrast Media | February 02, 2017
Lantheus Medical Imaging Inc. announced U.S. Food and Drug Administration (FDA) approval of a label update for Definity...
CT, computed tomography, IV contrast media, acute kidney injury risk, Annals of Emergency Medicine study

A new study in Annals of Emergency Medicine finds no association between intravenous contrast media used in computed tomography (CT) and kidney damage. Roughly 80 million doses of IV contrast media are given every year. Credit: American College of Emergency Physicians

News | Contrast Media | January 30, 2017
Intravenous contrast media (typically iohexol or iodixanol) used in computed tomography (CT) does not appear to be...
GE Healthcare, Optison ultrasound contrast agent, FDA labeling change, cardiac shunts, intra-arterial injection
Technology | Contrast Media | October 04, 2016
GE Healthcare announced that the U.S. Food and Drug Administration (FDA) has approved a label change for the ultrasound...
Overlay Init